{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:01:30Z","timestamp":1789844490100,"version":"4.0.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,19]]},"DOI":"10.7759\/cureus.116554","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:02:55Z","timestamp":1789840975000},"source":"Crossref","is-referenced-by-count":0,"title":["Frequency and Clinical Correlates of Sarcopenia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease"],"prefix":"10.7759","author":[{"given":"Tahseer","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda Batool","family":"Tirmizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Naeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abida","family":"Bukhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha Ali","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Irfan","family":"Jamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella ME","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al.. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023, 79:1542-56. 10.1016\/j.jhep.2023.06.003","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","unstructured":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024, 81.492-542. 10.1016\/j.jhep.2024.04.031","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.19615","article-title":"Metabolic dysfunction-associated steatotic liver disease in adults: a review","volume":"335","author":"Tilg H","year":"2026","unstructured":"Tilg H, Petta S, Stefan N, Targher G. Metabolic dysfunction-associated steatotic liver disease in adults: a review. JAMA. 2026, 335:163-74. 10.1001\/jama.2025.19615","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v31.i31.110481","article-title":"Skeletal muscle alterations in metabolic dysfunction-associated steatotic liver disease: a critical review of diagnostic, mechanistic, and therapeutic intersections","volume":"31","author":"Gupta V","year":"2025","unstructured":"Gupta V, Krishnamoorthy A. Skeletal muscle alterations in metabolic dysfunction-associated steatotic liver disease: a critical review of diagnostic, mechanistic, and therapeutic intersections. World J Gastroenterol. 2025, 31:110481. 10.3748\/wjg.v31.i31.110481","journal-title":"World J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2024.07.006","article-title":"The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis","volume":"43","author":"Li X","year":"2024","unstructured":"Li X, He J, Sun Q. The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis. Clin Nutr. 2024, 43:2005-16. 10.1016\/j.clnu.2024.07.006","journal-title":"Clin Nutr"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.02.013","article-title":"Sarcopenia among patients with nonalcoholic fatty liver disease (NAFLD) is associated with advanced fibrosis","volume":"21","author":"Harring M","year":"2023","unstructured":"Harring M, Golabi P, Paik JM, et al.. Sarcopenia among patients with nonalcoholic fatty liver disease (NAFLD) is associated with advanced fibrosis. Clin Gastroenterol Hepatol. 2023, 21:2876-2888.e5. 10.1016\/j.cgh.2023.02.013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41387-023-00250-6","article-title":"Metabolic associated fatty liver disease and sarcopenia additively increase mortality: a real-world study","volume":"13","author":"Zhao Q","year":"2023","unstructured":"Zhao Q, Yin Y, Deng Y. Metabolic associated fatty liver disease and sarcopenia additively increase mortality: a real-world study. Nutr Diabetes. 2023, 13:21. 10.1038\/s41387-023-00250-6","journal-title":"Nutr Diabetes"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.01.020","article-title":"Myosteatosis, but not sarcopenia, predisposes NAFLD subjects to early steatohepatitis and fibrosis progression","volume":"21","author":"Hsieh YC","year":"2023","unstructured":"Hsieh YC, Joo SK, Koo BK, et al.. Myosteatosis, but not sarcopenia, predisposes NAFLD subjects to early steatohepatitis and fibrosis progression. Clin Gastroenterol Hepatol. 2023, 21:388-397.e10. 10.1016\/j.cgh.2022.01.020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12937-025-01081-0","article-title":"Correlation of sarcopenia with progression of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: a study from two cohorts in China and the United States","volume":"24","author":"Zhang F","year":"2025","unstructured":"Zhang F, Liu L, Li W. Correlation of sarcopenia with progression of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: a study from two cohorts in China and the United States. Nutr J. 2025, 24:6. 10.1186\/s12937-025-01081-0","journal-title":"Nutr J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"Karlas T","year":"2017","unstructured":"Karlas T, Petroff D, Sasso M, et al.. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017, 66:1022-30. 10.1016\/j.jhep.2016.12.022","journal-title":"J Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL clinical practice guidelines for the management of patients with decompensated cirrhosis","volume":"69","year":"2018","unstructured":"EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018, 69.406-60. 10.1016\/j.jhep.2018.03.024","journal-title":"J Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","unstructured":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024, 105.S117-314. 10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines. Circulation. 2022, 145:e895-e1032. 10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14719","article-title":"Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease","volume":"41","author":"Hsieh YC","year":"2021","unstructured":"Hsieh YC, Joo SK, Koo BK, Lin HC, Kim W. Muscle alterations are independently associated with significant fibrosis in patients with nonalcoholic fatty liver disease. Liver Int. 2021, 41:494-504. 10.1111\/liv.14719","journal-title":"Liver Int"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2019.12.012","article-title":"Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment","volume":"21","author":"Chen LK","year":"2020","unstructured":"Chen LK, Woo J, Assantachai P, et al.. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020, 21:300-307.e2. 10.1016\/j.jamda.2019.12.012","journal-title":"J Am Med Dir Assoc"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2013.05.018","article-title":"SARC-F: a simple questionnaire to rapidly diagnose sarcopenia","volume":"14","author":"Malmstrom TK","year":"2013","unstructured":"Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc. 2013, 14:531-2. 10.1016\/j.jamda.2013.05.018","journal-title":"J Am Med Dir Assoc"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12754","article-title":"Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease","volume":"12","author":"Chun HS","year":"2021","unstructured":"Chun HS, Kim MN, Lee JS, et al.. Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease. J Cachexia Sarcopenia Muscle. 2021, 12:1168-78. 10.1002\/jcsm.12754","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-024-03192-0","article-title":"The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations","volume":"24","author":"Feng Z","year":"2024","unstructured":"Feng Z, Zhao F, Wang Z, Tang X, Xie Y, Qiu L. The relationship between sarcopenia and metabolic dysfunction-associated fatty liver disease among the young and middle-aged populations. BMC Gastroenterol. 2024, 24:111. 10.1186\/s12876-024-03192-0","journal-title":"BMC Gastroenterol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13099","article-title":"The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population","volume":"13","author":"Seo JY","year":"2022","unstructured":"Seo JY, Cho EJ, Kim MJ, et al.. The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population. J Cachexia Sarcopenia Muscle. 2022, 13:2953-60. 10.1002\/jcsm.13099","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16261","article-title":"MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: a nationwide study","volume":"38","author":"Han E","year":"2023","unstructured":"Han E, Chun HS, Lee YH, et al.. MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: a nationwide study. J Gastroenterol Hepatol. 2023, 38:1598-609. 10.1111\/jgh.16261","journal-title":"J Gastroenterol Hepatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.12.043","article-title":"Association of physical activity with risk of liver fibrosis, sarcopenia, and cardiovascular disease in nonalcoholic fatty liver disease","volume":"21","author":"Chun HS","year":"2023","unstructured":"Chun HS, Lee M, Lee HA, et al.. Association of physical activity with risk of liver fibrosis, sarcopenia, and cardiovascular disease in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2023, 21:358-369.e12. 10.1016\/j.cgh.2021.12.043","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100171","article-title":"Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease","volume":"2","author":"Golabi P","year":"2020","unstructured":"Golabi P, Gerber L, Paik JM, Deshpande R, de Avila L, Younossi ZM. Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease. JHEP Rep. 2020, 2:100171. 10.1016\/j.jhepr.2020.100171","journal-title":"JHEP Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.08.019","article-title":"Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis","volume":"66","author":"Koo BK","year":"2017","unstructured":"Koo BK, Kim D, Joo SK, et al.. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol. 2017, 66:123-31. 10.1016\/j.jhep.2016.08.019","journal-title":"J Hepatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13351","article-title":"Impact of anthropometric parameters on outcomes in Asians with metabolic dysfunction-associated fatty liver disease","volume":"14","author":"Choi KY","year":"2023","unstructured":"Choi KY, Kim TY, Chon YE, et al.. Impact of anthropometric parameters on outcomes in Asians with metabolic dysfunction-associated fatty liver disease. J Cachexia Sarcopenia Muscle. 2023, 14:2747-56. 10.1002\/jcsm.13351","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.11.031","article-title":"Risk stratification for sarcopenic obesity in subjects with nonalcoholic fatty liver disease","volume":"21","author":"Chun HS","year":"2023","unstructured":"Chun HS, Lee M, Lee HA, et al.. Risk stratification for sarcopenic obesity in subjects with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2023, 21:2298-2307.e18. 10.1016\/j.cgh.2022.11.031","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/534445-frequency-and-clinical-correlates-of-sarcopenia-in-patients-with-metabolic-dysfunction-associated-steatotic-liver-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:02:56Z","timestamp":1789840976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/534445-frequency-and-clinical-correlates-of-sarcopenia-in-patients-with-metabolic-dysfunction-associated-steatotic-liver-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.116554","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,19]]}}}